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In patients with left ventricular heart failure (HF), the development of pulmonary hypertension (PH) and right ventricular (RV) dysfunction are
frequent and have important impact on disease progression, morbidity, and mortality, and therefore warrant clinical attention. Pulmonary hyper-
tension related to left heart disease (LHD) by far represents the most common form of PH, accounting for 65–80% of cases. The proper distinc-
tion between pulmonary arterial hypertension and PH-LHD may be challenging, yet it has direct therapeutic consequences. Despite recent
advances in the pathophysiological understanding and clinical assessment, and adjustments in the haemodynamic definitions and classification
of PH-LHD, the haemodynamic interrelations in combined post- and pre-capillary PH are complex, definitions and prognostic significance of
haemodynamic variables characterizing the degree of pre-capillary PH in LHD remain suboptimal, and there are currently no evidence-based re-
commendations for the management of PH-LHD. Here, we highlight the prevalence and significance of PH and RV dysfunction in patients with
both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), and provide insights into the complex patho-
physiology of cardiopulmonary interaction in LHD, which may lead to the evolution from a ‘left ventricular phenotype’ to a ‘right ventricular
phenotype’ across the natural history of HF. Furthermore, we propose to better define the individual phenotype of PH by integrating the clinical
context, non-invasive assessment, and invasive haemodynamic variables in a structured diagnostic work-up. Finally, we challenge current defini-
tions and diagnostic short falls, and discuss gaps in evidence, therapeutic options and the necessity for future developments in this context.
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Introduction
Pulmonary hypertension (PH) is a frequent condition, which may
occur as a consequence of pulmonary vascular disease, chronic
left heart or lung disease, pulmonary embolism, or other aetiolo-
gies.1 –3 Among the various PH groups, PH associated with left heart
failure (HF) represents by far the most common form of PH. In fact,
left heart diseases (LHD) account for 65–80% of PH cases. Where-
as targeted therapies are available for pulmonary arterial hyperten-
sion (PAH),3,4 these treatments have not been adequately evaluated
or are not indicated and may even be harmful in patients with PH
related to LHD. It is therefore of key importance to establish a pre-
cise diagnosis and classification of PH before treatment decisions
are made. However, in clinical practice, there are significant incon-
sistencies, which are a matter of concern: on one hand, patients with
PH and occult LHD are frequently misclassified as PAH and treated
with PAH-specific drugs, or patients with PH of unclear origin re-
ceive targeted therapy without proper classification. On the other
hand, HF is often associated with PH and RV dysfunction, which
have an important impact on disease progression, morbidity, and
mortality, and this tends to be underestimated in the field of HF.5
Nevertheless, the haemodynamic interrelations when a pre-capillary
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component is present in post-capillary PH are complex, and the effi-
cacy and safety of targeted PH therapies remain unproven. Here, we
aim to highlight the prevalence and significance of PH and RV dysfunc-
tion in patients with left ventricular (LV) HF, provide insights into the
complex pathophysiology of cardiopulmonary interaction in LHD,
challenge current definitions and diagnostic short falls, and to discuss
therapeutic options and the necessity for future developments in this
context.
Haemodynamic definitions and
classification of pulmonary
hypertension related to left heart
disease
Regardless of the origin, PH is defined by a mean pulmonary artery
pressure (PAP) ≥25 mmHg.1,6 Based on the left-sided filling pres-
sure [determined either as LV end-diastolic pressure (LVEDP), left
atrial pressure (LAP), or pulmonary arterial wedge pressure
(PAWP)], the haemodynamic definition further distinguishes pre-
(≤15 mmHg) and post-capillary PH (.15 mmHg). In post-capillary
PH, the elevation of PAWP leads to a proportionate increase of the
mean PAP, maintaining a normal transpulmonary pressure gradient
(TPG ¼ mPAP – PAWP) ,12 mmHg, and low pulmonary vascular
resistance (PVR) ,3 Wood units (WU) or ,240 dynes s cm25.
However, chronic elevation of the left-sided filling pressure asso-
ciated with neurohormonal and other mediator activation as well
as neurogenic effects may cause excess vasoconstriction with or
without vascular remodelling leading to a ‘disproportionate’ in-
crease of the PAP, and thus resulting in an elevated TPG and PVR,
which has been described as ‘reactive’, ‘out-of-proportion’, or
‘mixed’ PH.1,7 While the TPG is influenced by volume load and
cardiac function, and does not prognosticate outcome in PH-LHD,8
the diastolic pressure gradient (DPG)—defined by the difference
between diastolic PAP and PAWP—is assumed to be less depend-
ent of stroke volume and loading conditions,9 and was shown to
correlate with pulmonary vascular remodelling in PH-LHD.10 These
findings led to the current terminology and classification of post-
capillary PH as either isolated post-capillary PH (Ipc-PH), if the
DPG is ,7 mmHg and/or PVR ≤3 WU, or combined post- and
pre-capillary PH (Cpc-PH), if the DPG is ≥7 mmHg and/ or PVR
.3 WU.11,12
Prevalence and significance of
pulmonary hypertension in left
ventricular heart failure
The presence and extent of PH and RV dysfunction—which are
both common in LV HF—are associated with disease progression,
decreased exercise tolerance, and an unfavourable outcome. Data
on the prevalence of PH in patients with HF yield variable numbers
and depend on the method of PAP measurement, the definition of
PH, and the populations studied. Although both HF with reduced
ejection fraction (HFrEF) and HF with preserved ejection fraction
(HFpEF) belong to the clinical syndrome of ‘heart failure’, they
constitute distinct entities with regard to pathophysiology, clinical
characteristics, haemodynamics, cardiopulmonary interaction, and
response to therapy, and should thus be viewed separately. In
HFrEF, the prevalence of PH as assessed by RHC was reported to
be between 40 and 75%.8,13,14 In patients with HFpEF, recent studies
utilizing either echocardiography or RHC indicated a PH prevalence
in a range between 36 and 83%.15– 17
A community-based study in patients with HF demonstrated that
pulmonary artery systolic pressure (PASP) estimated by echocardi-
ography strongly predicted all-cause and cardiovascular mortality in-
dependently of known predictors of outcome.18 While numerous
studies have consistently shown an inverse correlation between
PH and survival, a combination of elevated PAP and reduced RV sys-
tolic function was particularly associated with an unfavourable out-
come in HFrEF.13 In HFpEF, studies demonstrated that the presence
of PH was also strongly associated with mortality.15 – 17 Further-
more, HFpEF patients commonly display RV dysfunction, which is
associated with elevated PAP, occurs at more advanced stages,
and represents a strong predictor of death.19,20
Haemodynamic parameters that are predictive of poor survival in
HF include an increased PAWP, mean PAP, and PVR, and a reduced
PA compliance/capacitance.8,14,21 – 23 Significant efforts were made
to better define PH-LHD and harmonize definitions. However,
there is still a debate on the best haemodynamic predictor of out-
come. Recent studies on the prognostic value of the DPG in
PH-LHD have yielded conflicting results.10,14,22 – 24 This may be
explained, at least in part, by the populations studied and by meth-
odological limitations including inconsistencies in data due to the
presence of negative DPG and elevated DPG in patients without
PH. The nature of the controversial value of the DPG in HF patients
needs to be further addressed in future studies. Recent data indicate
that—depending on the consideration of the DPG and/or PVR—the
prevalence of Cpc-PH in patients with HF is 12–38%.10,14 The
above data collectively indicate that PH and RV dysfunction are fre-
quent and associated with a poor outcome in patients with LV HF.
Pathobiology of pulmonary
hypertension related to left heart
disease
The pathobiology of PH in left HF is complex and highly heteroge-
neous, and remains incompletely understood. Pulmonary hyperten-
sion primarily results from the passive backward transmission of
elevated left-sided filling pressures, which occur as a consequence
of systolic or diastolic LV dysfunction (Figure 1).11 Furthermore,
functional mitral regurgitation (MR) will result in elevations of LAP
and PAP, which usually worsen during exercise. In addition to LV re-
modelling and dysfunction, an increase in LA size (which is relatively
load-independent and serves as a marker of morbidity and mortality
in HF), interstitial fibrosis causing LA stiffness, and reduced LA com-
pliance, as well as impaired LA contractility, contribute to pathogen-
ic alterations in the pulmonary circuit and right heart (Figure 2).
These alterations of LA diastolic and systolic properties affect car-
diac filling and output, and the backward transmission of elevated
left-sided filling pressures leads to an increase of pulmonary pres-
sures, particularly during exercise.25,26 Consistently, LA dysfunction
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relates to symptom onset in patients with HFpEF.27 In addition to its
pathophysiological significance, LA dysfunction may also determine
treatment responses to targeted PH therapies in patients with LHD,
since lowering of PVR and increased pulmonary blood flow may lead
to increased PAWP and pulmonary oedema in patients with re-
duced LA compliance.
In the pulmonary circulation, sudden increases of LAP may cause
‘alveolar-capillary stress failure’, a reversible barotrauma altering
endothelial permeability and allowing leakage of erythrocytes, pro-
teins, and fluid into the alveolar lumen, thus causing interstitial and
alveolar oedema. Sustained elevation of left-sided filling pressure
and pulmonary venous pressure may be accompanied by superim-
posed components in the pulmonary circuit, which include de-
creased NO availability, increased expression of endothelin-1,
desensitization to natriuretic peptide-induced vasodilatation, infil-
tration of inflammatory cells, and neurogenic or metabolic factors.11
Furthermore, hypoxia promotes vasoconstriction and growth re-
sponses in the pulmonary circuit,28 and tachyarrhythmias, particu-
larly atrial fibrillation, may precipitate PH in patients with LV HF.
These additional components may trigger pulmonary arterial vaso-
constriction, and—over time—structural remodelling of small
pulmonary resistance arteries, indicative of a pre-capillary component
of PH where PAP further increases in excess of PAWP elevation
(Figure 1). Indeed, pulmonary arteriolar remodelling similar to PAH
has been described in severe PH-LHD, particularly in patients with
Cpc-PH (DPG ≥7 mmHg).10 Histopathological changes include
thickening of the alveolar-capillary membrane, medial hypertrophy,
intimal and adventitial fibrosis, and luminal occlusion in small pulmon-
ary arterioles, whereas ‘plexiform lesions’ pathognomonic of PAH are
not usually found.10,29,30 The fact that unloading of the LV by implant-
ation of a LV assist device (LVAD) in patients with HFrEF and severe
‘fixed’ PH may substantially lower or even normalize PAP over time
indicates that the alterations in the pulmonary circulation are partly
reversible at least in some patients.31,32 In contrast to the systemic cir-
culation, where vascular compliance is mainly determined by the aor-
ta, arterial compliance in the lung is distributed over the entire
pulmonary vascular bed, so that resistance (R) and compliance (C)
are predominantly determined by the small resistance vessels. Hence,
pulmonary arteriolar remodelling mainly contributes to the increase
in PVR and reduced PA compliance in Cpc-PH.
Of interest, there is an inverse relation between R and C in the
pulmonary circulation, and this holds true in PH-LHD.22,33 The
product of R and C (RC time) determines the drop in PAP after pul-
monary valve closure. It was found that in left HF with increased
PAWP, the RC time under the influence of the increased PAWP
is slightly decreased in comparison with PAH (Figure 3). Whether
this is due to abnormal pulmonary venous remodelling, increased
pulmonary vascular tone in left HF or just the consequence of the
increased wedge pressure on the RC time calculations remains un-
known. It has been suggested that the pressure gradient between
Figure 1 Cardiopulmonary interaction and pathobiology of pulmonary hypertension (PH) in left ventricular heart failure. Shown is (i) the back-
ward transmission of elevated left ventricular filling pressures into the pulmonary circulation (post-capillary haemodynamic profile), (ii) potential
superimposed components contributing to the extent of PH (leading to a pre-capillary component),11 which may be associated with (iii) pulmonary
vascular remodelling in some patients, thus leading to (iv) right ventricular strain and dysfunction over time. Right ventricular (RV) dilation and
increase in wall stress/tension (internal RV afterload) result in elevated myocardial oxygen consumption, which with concomitant reduction in
coronary perfusion gradient leads to RV ischaemia and progressive RV failure.
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the diastolic PAP and PAWP (DPG) is less dependent on volume
load and stroke volume than the TPG, and that an elevated DPG
may therefore be a better indicator of a pre-capillary component
of PH.9 However, the DPG may not be an ideal parameter, as it is
subject to inaccuracies related to heart rate, hypoxia, catheter
whip, utilizing computer-generated measurements, and the pres-
ence of negative values or elevated DGP without PH. While in
two retrospective studies, the DPG was shown to be a predictor
of survival in PH-LHD,10,22 two other studies failed to demonstrate
a prognostic impact of the DPG in patients with cardiomyopathy or
heart transplantation and PH.14,24 Thus, its role for prognostication
of survival and/or response to PH therapies must be further ex-
plored. Another implication of the constant RC is that based on
the inverse relationship between compliance and resistance, PA
compliance is a more sensitive marker for early disease than PVR.
Indeed, a reduced PA compliance and abnormal RV/PA coupling
Figure 2 Left atrial (LA) remodelling and dysfunction in heart failure. (A) Phases of LA function. PEV, passive empting volume ¼ Vmax – Vp; CV,
conduit volume ¼ LV stroke volume – (Vmax– Vmin); AEV, active emptying volume ¼ Vp – Vmin (modified from Rossi et al.25). (B) Left atrial pres-
sure–volume loops in normal LA function (left) and LA dysfunction (right). (C) Left atrial imaging by cardiac magnetic resonance imaging (cMRI) in
a patient with pulmonary arterial hypertension and normal LA function (left) vs. LA enlargement and dysfunction in a patient with left heart disease
(right) (cMRI movies may be downloaded from the Supplementary material online).
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are found even in early stages of HFpEF, and PA compliance appears
to be prognostically relevant even with normal PVR.21 –23,34,35
The elevations of pulmonary pressures and PVR represent an in-
crease of both resistive and pulsatile RV afterload, which results in
dilatation and maladaptive remodelling of right heart chambers,
functional tricuspid regurgitation, and ultimately RV dysfunction
and failure. Pathological changes of the RV include hypertrophy, fi-
brosis, dilatation, and a change in RV shape from a crescent to a
more spherical shape, which is associated with functional tricuspid
regurgitation and elevated right atrial pressure (RAP). Right ven-
tricular dysfunction resulting in low cardiac output is a key determin-
ant of outcome in PH-LHD. In fact, the prognostic significance of an
elevated PAP in HF increases with the degree of RV dysfunction ir-
respective of LVEF.13,19 However, the relationship between the se-
verity of PH and RV dysfunction is not ‘linear’, as some patients with
severe PH display normal RV function. In summary, a dysfunctional
RV and clinical signs of right HF in patients with LHD occur as a con-
sequence of pathological changes at the level of the ventricles, atrio-
ventricular valves, and atria in both the left and right heart, and
complex pathomechanisms of cardiopulmonary interaction affect-
ing PVR and PA compliance determine the impact of LHD on the
right heart (Figure 3).
Left vs. right ventricular phenotype
The current knowledge about the heterogeneity of PH in LV HF and
the reasons, why some patients develop severe PH and RV dysfunc-
tion whereas others do not, remains limited. Two factors may be
key: (i) the susceptibility for pulmonary vascular disease (due to gen-
etic factors and/or environmental stressors and/or comorbidities)
and (ii) the factor ‘time’. In many cases, only a ‘snapshot’ of a patient
is considered during the course of HF development and
progression. However, in HF patients who are susceptible for pul-
monary vasculopathy, a potential evolution of LV disease to right
ventricular (RV) dilatation and functional impairment as a result of
PH may be observed. During this evolution, the heart alters progres-
sively across a spectrum from a picture of an abnormal LV with an
otherwise normal RV (‘left ventricular phenotype’) into a picture of a
dilated and functionally impaired RV which may even dominate over
the LV abnormality (‘right ventricular phenotype’) (Figure 4). The ap-
pearance of LV or RV phenotype depends on the point in this evo-
lution that cardiac imaging is undertaken. This is supported by the
fact that RV dysfunction in HFpEF is associated with more advanced
stages of the disease.20 Examples of PH and RV phenotype develop-
ing over time—depending on patient’s susceptibility—are depicted
in Supplementary material online, Figure S1. Mortality increases as
the RV phenotype develops. It must be emphasized that invasive
haemodynamics are not always reliable in differentiating between
different phenotypes across the spectrum because the use of diure-
tics and alterations in fluid status may influence ventricular filling
pressures. While post-capillary haemodynamics indicate that LV dis-
ease is driving PH, pre-capillary haemodynamics do not exclude LV
disease with certainty.
The dilemma of pulmonary arterial
wedge pressure measurements to
discriminate pre- and
post-capillary pulmonary
hypertension
Pulmonary arterial wedge pressure measurements are prone to sig-
nificant errors which have direct implications on PH classification
Figure 3 Sequence of pathophysiological factors contributing to pulmonary hypertension in left ventricular heart failure. Backward transmission
of left- to right-sided pathological features at the level of the ventricles, atrioventricular valves, and atria. Data derived from Tedford et al.33 show-
ing that in left heart failure related pulmonary hypertension with increased wedge pressure the RC time is constant, but slightly decreased (left-
ward shift) (images containing video loops may be downloaded from the Supplementary material online).
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and treatment decisions. Limitations and uncertainties include the
threshold level of PAWP that discriminates between pre- and post-
capillary PH, technical difficulties to obtain correct recording of
pressure tracings, as well as lack of proper standardizations of cali-
bration (zero level), and particularly the method of PAWP reading in
relation to the respiratory cycle (Table 1).
Although physicians use the same threshold level of 15 mmHg
to discriminate between pre- and post-capillary PH world-
wide,1,6,36 ‘expert centres’ utilize different methods of measure-
ment, which may produce a mean difference of 4–6 mmHg.37 – 39
These differences are due to respirophasic variations of intra-
thoracic pressures, resulting in lower values during inspiration,
and higher values during expiration (Figure 5A). Additional sources
of error include uncertainties about the threshold level and the
impact of volume load (Figure 5B). Directly opposing studies
have recently been published regarding the method of PAWP
measurement and potential misclassifications between PAH and
PH due to LHD (particularly HFpEF). Whereas one study indicated
that the use of a digital mean value averaged across the respiratory
cycle instead of the end-expiratory mean value frequently leads to
misclassifications of PH-HFpEF as PAH,37 the other study re-
vealed that reliance on end-expiratory PAWP instead of the digital
mean value may lead to misclassifications of pre- as post-capillary
PH38 (see Figure 5A). This dilemma highlights the high degree of
variability, and the differences may in part be explained by the
patient populations studied: while the end-expiratory method
appears to be appropriate to distinguish between PAH and
HFpEF, the digital mean value may be more appropriate in
patients with COPD in whom respiratory swings are usually
more pronounced.37,38,41
In clinical practice, misclassifications of PH-HFpEF as PAH and in-
appropriate treatment of such patients with targeted PAH drugs ap-
pears much more common than vice versa. Furthermore, the
end-expiratory method of PAWP reading was recently shown to
correlate well with direct measurement of LVEDP, and to a pre-
capillary pattern.37,42 In order to minimize the risk of misclassifying
PH-LHD as PAH, at least in elderly patients and those with signs or
risk factors of LHD, and in accordance with the recommendations
of the 5th World Symposium on Pulmonary Hypertension 2013 in
Nice,6,11 the following standardization of PAWP measurement ap-
pears most appropriate, particularly to discriminate between PAH
and PH due to LHD:
† Zero level: the zero reference level should be set at the
mid-thoracic position, which represents the level of the left
atrium.39
† Pulmonary arterial wedge pressure threshold: the threshold level to
discriminate between pre- and post-capillary PH should be
15 mmHg, but suspicion for PH-HFpEF should be raised at values
between 12 and 15 mmHg particularly in diuresed patients and/
or risk factors for LHD.6,11
† Reading of PAWP: PAWP should be measured at end-expiration,
where the effects of intra-thoracic pressure swings are minimal.6
Patients should not hold their breath, and must not erroneously
perform a Valsalva manoeuvre.
† Direct measurement of LVEDP: should be considered if PAWP is
not reliably measurable or uncertain, or if significant LHD is
suspected.
Nevertheless, physicians have to be aware of the limitations of PAWP
measurement in general (Table 1), and of potential misclassifications
Figure 4 ‘Left ventricular phenotype’ vs. ‘right ventricular phenotype’ in pulmonary hypertension associated with left heart disease. Shown is the
spectrum of right ventricular dysfunction and presentation, the impact on mortality, therapeutic implications, and resting pulmonary
haemodynamics.
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when using either the digitized mean value or the end-expiratory
method of PAWP reading. In patients with COPD and pronounced
respiratory swings, utilization of the digitized mean value may be
appropriate.
Distinction between pulmonary
arterial hypertension and
pulmonary hypertension
associated with left heart disease
Current guidelines indicate that RHC is mandatory to confirm the
diagnosis of PH, and—based on the PAWP—to allow for a precise
haemodynamic classification as pre- or post-capillary PH.12 How-
ever, due to the above mentioned limitations of PAWP measure-
ment and interpretation, and to the high degree of variability,
this is not always applicable in clinical practice. While RHC is in-
deed required for proper diagnostic work-up in PH, invasively
measured haemodynamics alone are in many cases not sufficient
to establish a precise diagnosis. Instead, an integrated interpret-
ation of invasive and non-invasive evaluations is required. Figure 6
provides a diagnostic algorithm/decision-making tree, which may
help to integrate RHC and non-invasive findings, and to better elu-
cidate the underlying cause and pathophysiology of PH in the con-
text of LHD. Patients suspected to have PH should undergo clinical
evaluation and basic non-invasive testing, and—if indicated—add-
itional tests should be performed. A predictive model incorporat-
ing medical history, ECG, and echocardiography data helps to
discriminate PAH from PH-LHD.43 Based on the results of a
comprehensive non-invasive work-up, a ‘suspected diagnosis’ should
be formulated. Clinical features, specific findings, and test results
that may be suggestive of either PAH or PH-LHD are listed
in Table 2.
Since here we focus on the differentiation between PAH and
PH-LHD, we do not specify other forms of PH (Nice Groups 3–5)
which should certainly be diagnosed or ruled out accordingly.2,6,12
In cases of mild PH and dominant LHD, further testing for PH is usu-
ally not required. Instead, left heart catheterization may be indicated,
and LHD treated. If PAH is suspected, or severe PH is present in
addition to (mild) LHD, invasive assessment of pulmonary haemo-
dynamics by RHC is usually indicated.
When performing RHC, there are three main tasks (three C’s)
(Figure 6):
(1) Confirm: the presence of PH should be confirmed by a mean
PAP ≥25 mmHg.
(2) Complete: it is crucial to obtain the complete set of pulmonary
haemodynamics; this includes measurement of PAP (systolic,
diastolic, and mean), RAP, cardiac output/cardiac index, mixed
venous oxygen saturation, and calculation of the TPG (mean
PAP – PAWP), DPG (diast PAP – PAWP), and PVR (mean
PAP – PAWP/CO). Furthermore, pulmonary haemodynamics
must always be interpreted in relation to systemic vascular re-
sistance (PVR/SVR ratio).
(3) Characterize: PH should be characterized as pre-, isolated post-
capillary, or combined post- and pre-capillary, based on the
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Table 1 Potential confounders and criteria of valid measurement, reading and interpretation of pulmonary arterial
wedge pressure tracings
Measurement and reading of pressure tracings
Measurement may be challenging
not possible in every patient (dilated arteries)
Zero point should be mid-thoracic
Point of reading end of normal expiration (during free respiration)
Factors preventing correct interpretation of pressure tracings
Diuretic use may artificially lower PAWP/LVEDP in patients with LHD
COPD prominent respiratory swings, digital mean method may be preferred
Atrial fibrillation variable/unreliable values due to interbeat variation
mean of five measurements should be calculated
High v-wave consider mitral regurgitation (diastolic LV dysfunction)
Thorax deformaties referencing may be difficult
Abdominal obesity raised intra-abdominal and intra-thoracic pressure
Criteria for valid PAWP measurement
PAWP value PAWP equal or lower than diastolic PAP
Pressure tracing similar to atrial pressure tracing (a- and v-wave)
Respirophasic variations respiratory swings visible
Catheter position stationary catheter position (fluoroscopy)
Aspiration free flow within the catheter (aspiration possible)
O2 saturation in occluding position, aspiration of oxygen-rich blood (SO2 .94%) from the distal lumen
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assessment of LV filling pressure either measured as PAWP or
LVEDP. When interpreting the pressure tracings, it is critical to
be aware of the limitations and sources of error with regard to
PAWP measurement (Table 1).
It is of key importance to ask whether the results obtained by inva-
sive measurement of haemodynamics are consistent with the ‘sus-
pected diagnosis’ based on the results of non-invasive testing. If
the answer is ‘yes’, then a ‘working diagnosis’ is established, and pa-
tients should be treated accordingly. If the answer is ‘no’, then non-
invasive measures—particularly echocardiographic parameters—
should be reconsidered, and invasive haemodynamics must be
interpreted in the clinical context. Of note, as the LVEDP depends
on the loading condition of the LV, unloading (e.g. by forced diuresis)
can decrease LVEDP (and consecutively PAWP) to values
,15 mmHg, even in patients with LHD. In cases of doubt, invasive
assessment of LV filling at rest and during a stress test (either exer-
cise or fluid challenge) may be performed. As HFpEF patients have a
steep end-diastolic pressure/volume relationship, even small
changes in volume are associated with a significant increase in filling
pressures, and a ‘volume challenge’ (e.g. infusion of 500 mL of saline
within 5–10 min) may be feasible to unmask occult pulmonary
Figure 5 Pulmonary arterial wedge pressure (PAWP). (A) Potential misclassifications between pre- and post-capillary pulmonary hypertension
depending on the method of PAWP reading.37,38 (B) Example of a patient with pulmonary hypertension-heart failure with preserved ejection frac-
tion before (left) and after (right) treatment with diuretics, illustrating the impact of volume load on pulmonary haemodynamics (modified from
Dumitrescu et al.40).
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venous hypertension.46 Based on current data, a PAWP
.18 mmHg may be considered as an abnormal response to fluid
challenge.47 An alternative may be the integration of exercise testing
into the diagnostic work-up.48 However, such tests lack proper
standardization and are awaiting further evaluation and validation
before their use in clinical practice can be recommended.
Figure 6 Differential diagnosis between pulmonary arterial hypertension (PAH, Nice Group 1) and pulmonary hypertension associated with
left heart disease (PH-LHD Nice Group 2). Shown is a diagnostic algorithm, integrating non-invasive tests, and haemodynamic variables assessed
by cardiac catheterization. For interpretation of non-invasive tests, see corresponding Table 2. *Limitations and uncertainties of pulmonary arterial
wedge pressure/left ventricular end-diastolic pressure measurement are depicted in Table 1. Ipc-PH, isolated post-capillary PH; Cpc-PH, combined
post- and pre-capillary PH.
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Non-invasive tools to differentiate
between pulmonary arterial
hypertension and pulmonary
hypertension-heart failure with
preserved ejection fraction
While systolic dysfunction in patients with PH-HFrEF is usually easy
to detect, the proper distinction between PAH and PH associated
with HFpEF is much more challenging. Regardless of the presence
of PH, there are reliable non-invasive tools that indicate the pres-
ence of diastolic LV dysfunction (Table 2).11,49 The gold standard
for the assessment of LV diastolic function is the invasive assessment
of the pressure–volume relationship which usually requires an esti-
mation of LV volume by the conductance method. It has been
shown that LV stiffness is a reliable characteristic in patients with
HFpEF.50,51 An alternative to the assessment of invasive haemo-
dynamics can be comprehensive echocardiography, which—in com-
bination with natriuretic peptides—is feasible to diagnose HFpEF as
proposed by a consensus statement.49 Echocardiographic assess-
ment for HFpEF includes estimation of LVEDP by E/E′, assessment
of left atrial size, E/A ratio, and deceleration time.52 It should be
noted, however, that echocardiographic parameters such as E/E′
also have their limitations in accurately diagnosing HFpEF. An inte-
grative score of five echocardiographic variables (RV/LV ratio, left
ventricular eccentricity index (LVEI), E/E′, RV forming apex, width
and inspiratory collapse of IVC) as well as additional parameters
such as the shape of the RV outflow tract Doppler envelope
(‘RVOT notching’) may be utilized to discriminate between pre-
and post-capillary PH.53,54 The presence of one or more of the above
findings should prompt one to suspect PH-HFpEF instead of PAH,
even if the left-sided filling pressure as assessed by PAWP or LVEDP
measurement during cardiac catheterization may be ,15 mmHg.
Treatment of pulmonary
hypertension in left ventricular
heart failure
The prognostic impact of PH and RV dysfunction in LV HF pro-
vides the rationale for targeting PH as a potential additional treat-
ment option in both HFrEF and HFpEF. However, it is critical to
precisely determine the cause and severity of PH, before any treat-
ment decisions are made. Therefore, a comprehensive diagnostic
work-up is necessary, and targeted HF treatments (medical/inter-
ventional) remain the only established therapies. Nevertheless,
the treatment options in HF—particularly HFpEF—remain lim-
ited, and the classification of PH may be challenging in individual
patients. In selected cases presenting with a ‘right ventricular
phenotype’ in whom PH and RV dysfunction are prominent, tar-
geted judicious PH therapy may be considered despite the pres-
ence of LHD.55
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Table 2 Results of non-invasive diagnostic tests may be suggestive of either pulmonary arterial hypertension or
pulmonary hypertension associated with left heart disease
Suggestive of PAH (Nice group 1) Suggestive of PH-LHD (Nice group 2)
a. Clinical
features
Younger age, familial cases, bendopneaa, risk factors for PAH: CTD,
CHD, severe liver disease, portal hypertension, HIV
Older age, hypertension, diabetes, CAD, BMI .30, pulmonary
congestion, history of pulmonary oedema, orthopnoea
b. ECG RV hypertrophy, right axis, RV strain LV hypertrophy (Sokolow–Lyon index: S in V1 + R in V6), left axis,
atrial fibrillation
c. ECHOb No signs of LHD, PASP elevated, RV. LV, RV hypertrophy/
dysfunction (TAPSE), RVOT notchingc, small LA, dilated IVC
Enlarged LA, LV hypertrophy, signs of systolic (EF) and/ordiastolic
(E/A, DT, E/E′) LV dysfunction, valvular disease
d. Chest
X-ray
Enlarged right heart chambers, dilated PA, peripheral PA pruning Pulmonary congestion, Kerley B lines, pleural effusions,
enlargement of left heart chambers
e. PFT/DLCO Normal/mild obstructive spirometry, normal or moderately
decreased DLCOd, low pcCO2 (≤36 mmHg)e
Normal/obstructive spirometry, normal DLCO (may be decreased
due to comorbid COPD), high pcCO2 (.36 mmHg)
e
f. Biomarkers BNP/NTproBNP elevated (not discriminate between
Groups 1 and 2)
BNP/NTproBNP elevated (not discriminate between group 1
and 2)
g. CPET Low PETCO2 at AT, decreasing during exercise; high VE/VCO2,
increasing during exercise
PETCO2 at AT normal or slightly lowered, not decreasing during
exercise, VE/VCO2 not increasing during exercise
h. HR-CT To diagnose or rule out parenchymal lung disease (not discriminate
between Groups 1 and 2)
To diagnose or rule out parenchymal lung disease (not discriminate
between Groups 1 and 2)
i. V/Q scan To diagnose or rule out CTEPH (not discriminate between
Groups 1 and 2)
To diagnose or rule out CTEPH (not discriminate between
Groups 1 and 2)
aBendopnea is typical in PAH, but may be found in HFrEF, particularly when associated with RV dysfunction and elevated RAP as described in Ref. 44.
bA score of five echocardiographic variables may be utilized to discriminate between pre-capillary PH (RV/LV ratio ≥1.0, LVEI .1.2, E/E′ ≤10, RV forming apex, IVC .20 mm
without inspiratory collapse) and post-capillary PH (RV/LV ratio ,1.0, LVEI ≤1.1, E/E′ .10, RV not forming apex, IVC ≤20 mm and collapsible).53
cRVOT notching.54
dMarked hypoxemia and low DLCO may suggest pulmonary veno-occlusive disease (PVOD).
eRole of the capillary pCO2 (pcCO2) described in Ref. 45. CTEPH, chronic thromboembolic pulmonary hypertension; CAD, coronary artery disease
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Treatment of left heart disease and
lowering of left-sided filling pressure
The clinical impact of elevated PAWP/LVEDP and PAP in patients
with LV HF warrants attention. Optimized treatment of the under-
lying LHD including medical treatments (reaching the target do-
sages) and interventional therapies (e.g. CRT, ICD, LVAD,
MitraClip) usually helps to lower left-sided filling pressure and is al-
ways the primary aim in HF patients. Nevertheless, the consider-
ation of pulmonary haemodynamics may be helpful, and volume
depletion is usually associated with a substantial reduction of left-
sided filling pressure (PAWP/LVEDP), PAP, and TPG (see
Figure 5C). In this context, the CHAMPION trial has shown that con-
sideration of the PAP (assessed by an implantable device) as an add-
itional treatment target profoundly reduced the rate of
HF-associated hospitalizations in both HFpEF and HFrEF.56,57 Of
note, reductions of PAP were not achieved by targeted PAH drugs
in this trial, but by optimized HF treatment including adjustment of
diuretics.
Repair of mitral regurgitation in heart
failure
Particularly in patients with HFrEF and dilated left-sided heart cham-
bers, functional MR is common, may represent the main cause of
PH, and leads to increased mortality.58 Even exercise-induced PH
and RV dysfunction were recently shown to be associated with ad-
verse outcome in patients with asymptomatic MR.59,60 There is
good evidence in patients with LV HF and functional MR, that proper
treatment of the mitral valve including catheter-based approaches
such as Mitral Clipping or Cardio-Band lead to substantial improve-
ment of pulmonary haemodynamics, including reductions of the
mean PAP and PAWP (mainly via reduction of the v-wave), and a
profound improvement of cardiac index.61 While the evidence re-
mains limited and outcome trials are still lacking, percutaneous mi-
tral valve repair was shown to improve clinical symptoms, exercise
capacity, quality of life, and HF-associated hospitalizations in HF pa-
tients.62 Hence, MR has to be considered as the potential cause of
PH in LV HF, and appropriate valve repair should be initiated in pa-
tients who are on optimized medical treatment.
Targeted treatment of pulmonary
hypertension in patients with left
ventricular heart failure
Based on the prognostic impact of PH and RV dysfunction in both
HFrEF and HFpEF, treatment of PH in addition to established HF
therapies may appear to be a promising approach. Targeted therap-
ies approved for the treatment of PAH include endothelin receptor
antagonists (ERAs), prostanoids, phosphodiesterase type 5 inhibi-
tors (PDE5i), and stimulators of soluble guanylate cyclase
(sGC).3,4 It should be emphasized that none of these compounds
are approved for the treatment of PH-LHD. A concern with the
use of targeted PAH drugs in patients with LHD is that pulmonary
vasodilation and increasing pulmonary blood flow in the presence of
elevated left-sided filling pressures may potentially lead to pulmon-
ary oedema and cardiac decompensation. Despite these concerns,
such compounds have been investigated in patients with HF.
Randomized controlled trials (RCTs) investigating the efficacy and
safety of ERAs and prostanoids have shown no benefit, or PH ther-
apies have even proved harmful (summarized in Refs 11,55). For in-
stance, the FIRST trial, which investigated intravenous epoprostenol
in patients with PH-HFrEF, was prematurely terminated due to a
trend for increased mortality in the treatment group when com-
pared with placebo. Notably, ERAs have only been investigated in
patients with HF in general without considering the presence of
PH, so their impact on PH-LHD remains unknown. Few data are
currently available in PH-HFpEF, and the use of ERAs may be asso-
ciated with an increased risk of peripheral oedema in such patients.
An ongoing Phase II trial (MELODY) currently investigates the safety
and potential efficacy of the novel ERA macitentan in patients with
HFpEF and Cpc-PH (Table 3).
More recent studies have focused on targeting the NO pathway
in patients with PH-LHD (Table 3). The randomized controlled RE-
LAX trial has shown that the PDE5i sildenafil did not improve peak
oxygen consumption (primary endpoint) and exercise capacity in
patients with HFpEF in the absence of PH.63 In a recent single-centre
RCT, sildenafil also failed to improve haemodynamics or exercise
capacity in 53 patients with HFpEF and Ipc-PH.64 On the other
hand, small single-centre studies have consistently shown that silde-
nafil improved haemodynamic parameters and exercise capacity in
patients with severe PH that was associated with either HFrEF or
HFpEF.65 – 67 A meta-analysis of six RCTs investigating the efficacy
and safety of PDE5i in patients with HFrEF—each performed in
small numbers of patients—revealed that additional use of a
PDE5i improved haemodynamics and exercise capacity, and re-
duced clinical symptoms and hospitalizations when compared
with placebo.68 However, such data should be interpreted with
great caution, as they were obtained in highly selected patients,
and data from larger RCTs are yet lacking.
An alternative way to modulate the NO pathway is the stimula-
tion of sGC. The sGC stimulator riociguat (which is approved for
PAH and inoperable CTEPH) was recently investigated in two
RCTs in PH-LHD. In patients with PH-HFrEF, the LEPHT trial failed
to reach the primary endpoint of lowering PAP vs. placebo, but led
to a substantial increase in cardiac index, resulting in lowering of
PVR.69 Likewise, a proof-of-concept trial testing the acute effects
of riociguat in patients with PH-HFpEF (DILATE) obtained similar
results.70 These findings may suggest a systemic and/or cardiac effect
of riociguat rather than pulmonary vasodilation. Targeting this path-
way in HF awaits further investigation.
Based on the current evidence, the use of targeted PAH therapies
in patients with PH related to left HF is discouraged, and selected
patients with Cpc-PH and/or RV phenotype should be referred to
centres with expertise in both HF and PH, and should—whenever
possible—be included into clinical trials.
Clinical relevance and future
considerations
In patients with LV HF, PH is a common and life-threatening compli-
cation that remains underestimated in clinical cardiology. Given the
relentlessly increasing incidence and prevalence of HF, particularly
HFpEF, and the poor prognosis of patients who develop PH and
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Table 3 Summary of recently completed and ongoing clinical trials in pulmonary hypertension associated with left heart disease
Drug n Start End Duration Primary endpoint Secondary endpoints
HF with reduced EF
Riociguat
LEPHT69
201 Results available 16 weeks Change in mPAP from baseline Haemodynamic and echocardiographic
variables, biomarker levels, safety,
pharmacokinetics
Sildenafil
Sil-HF (NCT01616381)
210 9/2012 6/2014 24 weeks Patient Global assessment 6MWD QoL, Kansas city questionnaire, safety
Tadalafil
PITCH-HF (NCT01910389)
2102 Study terminated
Febuary 2014a
Up to 54 months Time to CV death or 1st HF
hospitalization
Biomarkers levels, exercise capacity,
QoL, safety
HF with preserved EF
Sildenafil
RELAX63
216 Results available 24 weeks Change in peak VO2 from baseline Exercise capacity, clinical status, QoL, safety
Sildenafil
Hoendermis et al.64
52 Results available 12 weeks Change in mPAP from baseline Change in PAWP, cardiac output, peak VO2
Riociguat
DILATE70
48 Results available 16 weeks Change in mPAP from baseline Haemodynamic and echocardiographic
variables, biomarker levels, safety,
pharmacokinetics
HF with EF .35%
Macitentan
MELODY-1 (NCT02070991)
60 5/2014 10/2015 12 weeks Safety and tolerability (fluid retention) PVR, haemodynamics, changes in TPG and
DPG, echocardiographic variables
(RV function)
All studies were performed in heart failure patients with and/or without preserved ejection fraction.
mPAP, mean pulmonary artery pressure; DPG, diastolic pressure gradient; HF, heart failure; PVR, pulmonary vascular resistance; QoL, quality of life; RV, right ventricle; 6MWD, six minute walking distance; TPG, transpulmonary pressure
gradient.
aThe study has been terminated by the funding agency.
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RV dysfunction secondary to LV HF, it is imperative to further im-
prove our understanding of the pathophysiology of PH-LHD, and
to establish an evidence-based approach for the management of HF
patients developing PH. Harmonized terminology and a new classifi-
cation of PH-LHD (Ipc-PH vs. Cpc-PH) have improved the clinical as-
sessment and should help prevent the inappropriate off-label use of
PAH drugs in PH-LHD. In addition, they provide better tools to iden-
tify a subset of patients with HF and PH who deserve special attention.
Despite significant achievements that were made recently, important
evidence gaps remain that need to be addressed in future studies.
Specific propositions
† Since cardiopulmonary interaction in HF is complex and variable,
the definitions and prognostic significance of haemodynamic vari-
ables characterizing the degree of pre-capillary PH in LHD need
to be further improved. This may be achieved by integrated mea-
sures of pulmonary vascular and RV function.
† As the differential diagnosis between pre- and post-capillary PH
remains challenging, an integrative approach considering the clin-
ical context, non-invasive assessment, and invasive haemodynam-
ic variables is critical. The role of volume challenge and exercise
stress testing to unmask occult LHD needs to be established and
requires standardization and validation.
† The evolution from an LV phenotype to an RV phenotype over
time as a result of PH requires further investigation. We need
to better understand the susceptibility for pulmonary vascular
disease in HF in a subset of patients (genetic predisposition, con-
tributing factors), and to collect data on the prevalence and tim-
ing of such an evolution, which will ideally help to predict which
patients with LHD will develop significant PH and RV dysfunction.
† Specifically, longitudinal studies should be performed that inves-
tigate the development of RV dysfunction in patients with LV HF
over time.
† Thus far, targeted PH therapies have never been investigated prop-
erly in PH-LHD. Carefully controlled randomized trials in larger
populations of well characterized patients (PH-HFrEF and
PH-HFpEF separately), with longer observation times, and defini-
tive endpoints are needed. In such trials, it must be assured that
patients are on optimized regimens of HF therapy and fluid balance
before randomization, which may be achieved by a ‘run-in’ phase.
† Proof-of-concept studies in limited numbers of haemodynamical-
ly well characterized patients, focusing on patients with Cpc-PH,
together with the improvement of non-invasive variables that
better characterize the degree of pre-capillary PH in PH-LHD,
may better inform larger RCTs.
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